Anaesthetic management of coronary artery bypass grafting in a patient with central core disease and susceptibility to malignant hyperthermia on statin therapy

British Journal of Anaesthesia

Volumn 91, Issue 5, 2003, Pages 744-747

  Johi, R R ^a   Mills, R ^b   Halsall, P J ^c   Hopkins, P M ^c  

^a WILLIAM HARVEY HOSPITAL   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Complications, central core disease; Complications, malignant hyperthermia; Heart, coronary artery, bypass grafting; Hormones, statins; Protein, aprotinin; Temperature, regulation, hypothermia

Indexed keywords

ACETYLSALICYLIC ACID; APROTININ; ATENOLOL; ATORVASTATIN; CAFFEINE; GLYCERYL TRINITRATE; HALOTHANE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE MONONITRATE;

ADULT; ANESTHESIOLOGICAL TECHNIQUES; ARTICLE; CASE REPORT; CORONARY ARTERY BYPASS GRAFT; FEMALE; GENE MUTATION; HUMAN; ISCHEMIC HEART DISEASE; MALIGNANT HYPERTHERMIA; PRIORITY JOURNAL; UNSTABLE ANGINA PECTORIS;

EID: 0242467609     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/aeg262     Document Type: Article

References (22)

1. Shy GM, Magee KR. A new congenital non-progressive myopathy. Brain 1956; 79: 610-9
2. McCarthy TV, Healy JM, Heffron JJ, et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature 1990; 343: 562-4
3. Kausch K, Lehmann-Horn F, Janka M, Wieringa B, Grimm T, Mueller CR. Evidence for linkage of the central core disease locus to the proximal long arm of human chromosome 19. Genomics 1991; 10: 765-9
4. McCarthy TV, Quane KA, Lynch PJ. Ryanodine receptor mutations in malignant hyperthermia and central core disease. Hum Mutat 2000; 15: 410-7
5. Sambuughin N, Nelson TE, Jankovic J, et al. Identification and functional characterisation of a novel ryanodine receptor mutation causing malignant hyperthermia in North American and South American families. Neuromuscul Disord 2001; 11: 530-7
6. Sambuughin N, McWilliams S, Bantel A, Sivakumar K, Nelson TE. Single-amino-acid deletion in the RYRI gene, associated with malignant hyperthermia susceptibility and unusual contraction phenotype. Am J Hum Genet 2001; 69: 204-8
7. Tilgen N, Zorzato F, Halliger-Keller B, et al. Identification of four novel mutations in the C-terminal membrane spanning domain of the ryanodine receptor I: association with central core disease and alteration of calcium homeostasis. Hum Mol Genet 2001; 10: 2879-87
8. Davis M, Brown R, Dickson A, et al. Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYRI mutation in New Zealand and Australian pedigrees. Br J Anaesth 2002; 88: 508-15
9. European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia susceptibility. Br J Anaesth 1984; 56: 1267-9
10. Robinson RL, Hopkins PM. A breakthrough in the genetic diagnosis of malignant hyperthermia. Br J Anaesth 2001; 86: 166-8
11. Urwyler A, Deufel T, McCarthy TV, West S, European Malignant Hyperthermia Group. Guidelines for the molecular testing of susceptibility to malignant hyperthermia. Br J Anaesth 2001; 86: 283-7
12. Byrick RJ, Rose DK, Ranganathan N. Management of a malignant hyperthermia patient during cardiopulmonary bypass. Can Anaesth Soc J 1982; 29: 50-4
13. Koehntop DE, Beebe DS, Belani KG. The safety of dantrolene in a patient with a severe cardiomyopathy requiring a heart transplant. Anesth Analg 1987; 85: 229-30
14. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36: 288-95
15. Omar M A, Wilson J P, Cox T S. Rhabdomyolysis and HMG-CoA reductase inhibitors. (Review). Ann Pharmacother 2001; 35: 1096-107
16. Guis S, Bendahan D, Kozak-Ribbens G, et al. Rhabdomyolysis and myalgia associated with anticholesterolemic treatment as potential signs of malignant hyperthermia susceptibility. Arthritis Rheum 2003; 49: 237-8
17. Boscoe MJ, Hunt BJ. Aprotinin: its role in modifying perioperative blood loss. Br J Clin Pract 1992; 46: 9-12
18. Bedirhan MA, Turna A, Yagan N, Tasci O. Aprotinin reduces postoperative bleeding and the need for blood products in thoracic surgery: results of a randomized double-blind study. Eur J Cardiothorac Surg 2001; 20: 1122-7
19. Stewart A, Newman L, Sneddon K, Harris M. Aprotinin reduces blood loss and need for transfusion in orthognathic surgery. Br J Oral Maxillofac Surg 2001; 39: 365-70
20. Findlay JY, Rettke SR, Ereth MH, Plevak DJ, Krom RA, Kuffner RP. Aprotinin reduces red blood transfusion in orthoptic liver transplantation: a prospective randomized double blind study. Liver Transpl 2001; 7: 802-7
21. Urban MK, Beckman J, Gordon M, Urquhart B, Boachie-Adjei O. The efficacy of antifibrinolytic in the reduction of blood loss during complex adult reconstructive spine surgery. Spine 2001; 26: 1152-6
22. Iaizzo PA, Kehler CH, Carr RJ, Sessler DI, Belani KG. Prior hypothermia attenuates malignant hyperthermia in susceptible swine Anesth Analg 1996; 82: 803-9